Evidence map›Paper›PMID 39330010›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Case Report of Concomitant Diagnosis of Locally Advanced Intrahepatic Cholangiocarcinoma and Solitary Plasmacytoma of T11 Vertebra: Impact on Diagnostic and Clinical Management.

Yann Touchefeu, Matthieu Barbaud, Laura Prin-Felix, Edouard Samarut, Bastien Jamet, Luc Ollivier, Damien Bouda

Abstract readCase Reports
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yann TouchefeuInserm CIC 1413, Hépato-Gastroentérologie, Institut des Maladies de l'Appareil Digestif (IMAD), CHU Nantes, Université de Nantes, F-44000 Nantes, France.ORCID 0000-0001-8421-3182
Matthieu BarbaudCRCI2NA, INSERM UMR1307, CNRS-ERL6075, Médecine Nucléaire, CHU Nantes, Université de Nantes, F-44000 Nantes, France.
Laura Prin-FelixService Hématologie, Nantes University Hospital, F-44000 Nantes, France.
Edouard SamarutNeurotraumatology and Neurosurgery Department, Nantes University Hospital, F-44000 Nantes, France.
Bastien JametCRCI2NA, INSERM UMR1307, CNRS-ERL6075, Médecine Nucléaire, CHU Nantes, Université de Nantes, F-44000 Nantes, France.ORCID 0000-0002-2145-9182
Luc OllivierDepartment of Radiation Oncology, Institut de Cancérologie de L'Ouest (ICO), F-44800 Saint-Herblain, France.ORCID 0000-0002-4270-5370
Damien BoudaIRIS GRIM-Site de Saint-Herblain-Santé Atlantique, F-44800 Saint-Herblain, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A solitary bone plasmacytoma is a rare tumor. Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma. We present the case of a 48-year-old female patient who consulted for recent back pain, with a final diagnosis of T10 solitary plasmacytoma and synchronous intrahepatic cholangiocarcinoma. Imaging suggested cholangiocarcinoma with bone metastasis. The patient underwent neurosurgical management with laminectomy, arthrodesis, and arthrectomy, with biopsies revealing monotypic kappa plasmacytic proliferation. Liver biopsies revealed an adenocarcinoma with expression of cytokeratin 19, cytokeratin 7, N-cadherin, and high expression of carbonic anydrase IX. The plasmacytoma was treated with external radiotherapy. The cholangiocarcinoma was treated with selective internal radiation therapy and concomitant systemic treatment with combinations of cisplatin and durvalumab, with capecitabine during radiotherapy, switched for gemcitabine after completion of irradiation. One year after initial management, imaging revealed a partial metabolic response of the intrahepatic cholangiocarcinoma, and a complete metabolic response of the plasmacytoma. This case illustrates the importance of not ignoring two primary tumors and the management of two concomitant treatments exploiting potential therapeutic synergies and limiting expected toxicities.

Indexed as

CholangiocarcinomaPlasmacytomaBile Duct NeoplasmsFemaleHumansMiddle Agedcholangiocarcinomaimmunotherapyradiotherapysolitary bone plasmacytoma

Identifiers

PMID39330010
PMCPMC11431636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.